CliffBio
small molecule

PYRIDOSTIGMINE BROMIDE

PYRIDOSTIGMINE BROMIDE

Loss of exclusivityJune 2038latest FDA-listed patent expiry
CompanyAmneal Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand namePYRIDOSTIGMINE BROMIDE
Active ingredientPYRIDOSTIGMINE BROMIDE
Strength105MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusDISCN

Listed patents

PatentExpiresType
11478425June 2038product
12042559June 2038product
10925833June 2038product
12233166June 2038product
10987311June 2038product
10881617June 2038product
11666536June 2038product
11911515June 2038product
11229606June 2038product

More from Amneal Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PYRIDOSTIGMINE BROMIDE patent cliff — loss of exclusivity June 2038 | CliffBio